The T cell landscape seems to be at least partly related to genetic aberrations, as patients with mutations in TP53 or myelodysplasia-related genes such as RUNX1 display lower infiltration of cytotoxic T cells and more pronounced immune effector dysfunction16,17. This evidence concerns the gene TP53 and Myelodysplasia.